Sanofi-Aventis on the Prowl
July 8, 2010 8:54 am by Dean Morel
The current focus of investors is on the short term gain that may be obtained from picking Sanofi’s acquisition target. Perhaps investors would be better rewarded by considering a long term investment in SNF.
As the image below highlights SNF appears on three of the guru screens at the NASDAQ Guru Stock Screener.
SNY appears on the following screens:
- Growth/Value Investor Strong Interest. Based on analysis of the book by James P O’Shaughnessy
- Value Investor Strong Interest. Based on analysis of the book by Benjamin Graham
- P/E Growth Investor Strong Interest. Based on analysis of the book by Peter Lynch
While articles like this one focus on US acquisition targets, better target may exist in countries like Australia, where biotech firms are relatively undervalued compared to their US counterparts.
More on this topic
(What's this?)
Allergan – Trade for Takeover Rumors
(, 7/6/10)
Momenta Crashes a $100 Billion Industry… And Scores an 80% Boost
(Investment U, 8/10/10)
Blink on Friday And Miss Massive Biotech Spikes (SNY, GENZ, MNTA, ZGEN, XOMA, TTHI, OSIR)
(tickerspy.com, 7/23/10)
No related posts.
Leave your response!